Dan joined Alta immediately following the firm’s founding in 1996, and was a co-founder of the Alta BioPharma effort.
Dan focuses on investments in biopharmaceutical products and therapeutics. He has been directly involved in the funding and development of over 25 life sciences companies. Dan is currently on the board of directors of a number of companies, including Alba Therapeutics, Esperion Therapeutics, Neothetics, Prolacta Bioscience and ViroBay. In addition, he led Alta’s investments in ChemGenex Pharmaceuticals, CoTherix, Definity Health, DiscoveRx, Dynavax, Endonetics, Ilex Oncology, InterMune, LJL Biosystems and Mako Surgical.
Prior to joining Alta, he was a senior investment banker at Montgomery Securities, focusing on life sciences companies. Dan is also a member of The President's Council of the Gladstone Institutes.
He holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.